Sotera Health (NASDAQ:SHC) Issues Earnings Results, Misses Expectations By $0.02 EPS

Sotera Health (NASDAQ:SHC) announced its quarterly earnings results on Thursday. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.02), Zacks reports. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. Sotera Health updated its FY 2025 guidance to 0.700-0.760 EPS.

Sotera Health Trading Down 10.0 %

Shares of NASDAQ:SHC traded down $1.36 during midday trading on Thursday, hitting $12.28. 3,153,775 shares of the stock traded hands, compared to its average volume of 956,965. The business’s 50 day moving average is $13.48 and its two-hundred day moving average is $14.54. The stock has a market capitalization of $3.48 billion, a PE ratio of 49.12 and a beta of 1.91. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. Sotera Health has a one year low of $10.71 and a one year high of $17.08.

Analyst Ratings Changes

SHC has been the topic of several recent analyst reports. Barclays lowered their target price on shares of Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Citigroup lifted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on Sotera Health in a research report on Friday, December 6th. They set a “neutral” rating and a $14.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Sotera Health currently has an average rating of “Moderate Buy” and an average target price of $16.08.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.